News and Trends 11 Jul 2023 NodThera first to show reduction in neuroinflammation with inflammasome inhibitor …NodThera, said: “Taken together, these initial findings represent the first unambiguous demonstration of modulation of neuroinflammation in a human population with an NLRP3 inflammasome inhibitor. In designing our Parkinson’s disease… July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2024 Booster launches to treat neurodegenerative diseases with proteasome activation …like Parkinson’s and Alzheimer’s. “We’re starting in neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. We know that proteasome dysfunction is present in these diseases, and multiple pathways are going wrong,… October 15, 2024 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jun 2024 Spotlight on Georgia’s biotech industry: Seven companies to know about in 2024 …Parkinson’s disease and other neurodegenerative disorders. Inhibikase’s work is based on targeting Abelson tyrosine kinases (c-Abl), which play an important role in neurodegeneration. Inhibikase employs its proprietary RAMP (Re-engineering Approach… June 25, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 Feb 2025 Seven companies using metabolomics to decode biology …its lead program. Sinopia Biosciences Disease area: Parkinson’s disease Candidate: SB-0110 Recent news: Received 2 SBIR grants in 2024 Sinopia Biosciences leverages its proprietary artificial intelligence and machine learning (AI/ML)… February 13, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s …blood-brain barrier. Neurodegenerative diseases are a hot topic, with age-related diseases like Alzheimer’s and Parkinson’s rising in prevalence. In the US alone, 5 million people suffer from Alzheimer’s disease, 1… January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2024 Top biotech deals of November 2024 …roll Partnerships focused on small molecules continue to be forged this month. U.S.-based Vesalius has partnered with GSK to develop small molecule inhibitor drugs for Parkinson’s disease. Vesalius will leverage… December 12, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 12 Jan 2024 Could natural killer cells transform Alzheimer’s treatment? …a few years ago, I think that will still be pretty dramatic.” Song said there are no side effects with the process. Future plans: NK cells for Parkinson’s disease and… January 12, 2024 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 8 Feb 2021 How Next-Generation Gene Therapy Tackles Complex Diseases …approach could be extended to other conditions involving the brain, such as Parkinson’s, ALS and pain. However, this kind of research is still at an early stage and it will… February 8, 2021 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 €260M fund addresses dementia investment shortfall …and Parkinson’s disease. Last year, it was also awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The others are AviadoBio (frontotemporal dementia (FTD)… March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Dec 2024 10 biotech companies to watch in 2025 …designation for Rett syndrome, fragile X syndrome, and infantile spasms A neuroscience company, Anavex Life Sciences, is developing small-molecule treatments for CNS disorders like Alzheimer’s disease, Parkinson’s disease, and Rett… December 16, 2024 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland …company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. Located in Switzerland,… December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation …A round in 2016 to develop treatments for Alzheimer’s, Parkinson’s, heart disease and cancer. While chronic inflammation may sound like a small inconvenience, it can result in serious conditions like… June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email